乙型肝炎病毒DNA检测在孕期的应用

孕妇血清乙型肝炎病毒(hepatitis B virus, HBV)DNA水平目前被认为是预测发生HBV母婴垂直传播的一个最重要指标和独立的危险因素。普遍认为，在充分考虑对孕妇及胎儿的利与弊的前提下，妊娠中、晚期口服安全性较高的核苷(酸)类抗病毒药物，可在分娩前明显降低母血中HBV DNA载量，从而最大程度地阻断HBV母婴垂直传播。抗病毒治疗4周后监测HBV DNA载量可以预估核苷(酸)类药物抗病毒治疗的远期有效性，以便及时调整治疗方案。HBV DNA检测在孕期的应用与何时应用对阻断HBV母婴垂直传播具有重要意义。

Application of hepatitis B virus DNA detection in pregnancy

Maternal serum hepatitis B virus (HBV) DNA level is considered as the most important and independent risk factor to predict the HBV vertical transmission rates. After fully considered the pros and cons of the mother and fetus, it′s generally agreed that administration of oral nucleoside antiviral in the second and third trimester can significantly reduce maternal serum HBV loads before delivery. Consequently, it will prevent maternal-fetal transmission of HBV to the maximum extent. HBV DNA level at week 4 of antiviral treatment predicts the long-term efficacy, which conduce to improve the therapeutic schedule. Overall, the measurement of HBV DNA level during pregnancy and the optimal time have important meaning for preventing maternal-fetal transmission of HBV.